FOXP3 and prostate carcinoma: The study has also pointed out the high expression of FOXP3 as a good predictor of the survival of a patient in prostate cancer, breast cancer, gastric cancer, and bladder cancer (Li et al., 2007; Wang et al., 2009; Winerdal et al., 2011; He et al., 2013; Fiori Lopes et al., 2014; Hao et al., 2014; Ma et al., 2014).